JP2023545096A5 - - Google Patents
Info
- Publication number
- JP2023545096A5 JP2023545096A5 JP2023521678A JP2023521678A JP2023545096A5 JP 2023545096 A5 JP2023545096 A5 JP 2023545096A5 JP 2023521678 A JP2023521678 A JP 2023521678A JP 2023521678 A JP2023521678 A JP 2023521678A JP 2023545096 A5 JP2023545096 A5 JP 2023545096A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089859P | 2020-10-09 | 2020-10-09 | |
| US63/089,859 | 2020-10-09 | ||
| PCT/IB2021/059232 WO2022074617A1 (en) | 2020-10-09 | 2021-10-08 | Combination of antibody-drug conjugate and parp1 selective inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545096A JP2023545096A (ja) | 2023-10-26 |
| JP2023545096A5 true JP2023545096A5 (https=) | 2024-10-10 |
Family
ID=78179469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521678A Pending JP2023545096A (ja) | 2020-10-09 | 2021-10-08 | 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230372527A1 (https=) |
| EP (1) | EP4225314A1 (https=) |
| JP (1) | JP2023545096A (https=) |
| KR (1) | KR20230084163A (https=) |
| CN (1) | CN116348115A (https=) |
| AU (1) | AU2021356762A1 (https=) |
| BR (1) | BR112023006337A2 (https=) |
| CA (1) | CA3195117A1 (https=) |
| IL (1) | IL301921A (https=) |
| MX (1) | MX2023004047A (https=) |
| TW (1) | TW202222350A (https=) |
| WO (1) | WO2022074617A1 (https=) |
| ZA (1) | ZA202305073B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| AU2022392822A1 (en) * | 2021-11-18 | 2024-05-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| EP4534537A4 (en) * | 2022-05-25 | 2025-12-10 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLE-DERIVED PARP INHIBITOR AND ITS USE |
| WO2024067694A1 (zh) * | 2022-09-30 | 2024-04-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| CN120936382A (zh) * | 2023-02-16 | 2025-11-11 | 阿斯利康(瑞典)有限公司 | 采用治疗性结合分子治疗癌症的组合疗法 |
| TW202535479A (zh) | 2023-12-05 | 2025-09-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US9707302B2 (en) * | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| SG11202100653YA (en) * | 2018-07-25 | 2021-02-25 | Daiichi Sankyo Co Ltd | Effective method for manufacturing antibody-drug conjugate |
| EA202190471A1 (ru) * | 2018-08-06 | 2021-05-24 | Дайити Санкио Компани, Лимитед | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина |
| KR102905497B1 (ko) * | 2018-12-11 | 2025-12-30 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 parp 저해제의 조합 |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
-
2021
- 2021-10-08 JP JP2023521678A patent/JP2023545096A/ja active Pending
- 2021-10-08 BR BR112023006337A patent/BR112023006337A2/pt unknown
- 2021-10-08 IL IL301921A patent/IL301921A/en unknown
- 2021-10-08 TW TW110137529A patent/TW202222350A/zh unknown
- 2021-10-08 US US18/248,283 patent/US20230372527A1/en active Pending
- 2021-10-08 AU AU2021356762A patent/AU2021356762A1/en active Pending
- 2021-10-08 MX MX2023004047A patent/MX2023004047A/es unknown
- 2021-10-08 WO PCT/IB2021/059232 patent/WO2022074617A1/en not_active Ceased
- 2021-10-08 EP EP21791471.2A patent/EP4225314A1/en active Pending
- 2021-10-08 CA CA3195117A patent/CA3195117A1/en active Pending
- 2021-10-08 KR KR1020237011575A patent/KR20230084163A/ko active Pending
- 2021-10-08 CN CN202180068558.1A patent/CN116348115A/zh active Pending
-
2023
- 2023-05-08 ZA ZA2023/05073A patent/ZA202305073B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023545096A5 (https=) | ||
| JP2023539715A5 (https=) | ||
| JP2023542066A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2023070678A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2020019787A5 (https=) | ||
| JP2023525120A5 (https=) | ||
| JPWO2020130125A5 (https=) | ||
| FI4516357T3 (fi) | Kasvaimen kasvua estävä yhdiste ja menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2010535713A5 (https=) | ||
| JP2015527318A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| RU2017139490A (ru) | Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2 | |
| HRP20210593T1 (hr) | Anti-her3 antitijelo-lijek konjugat | |
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| JP2008500815A5 (https=) | ||
| JP2015528818A5 (https=) | ||
| JP2024533356A5 (https=) | ||
| CN106999606A (zh) | 抗体药物偶联物 | |
| JP2020526584A5 (https=) | ||
| JP2020534300A5 (https=) | ||
| JP2019524713A5 (https=) |